Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Up 709.3% in January

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 980,100 shares, an increase of 709.3% from the December 31st total of 121,100 shares. Based on an average daily trading volume, of 335,500 shares, the days-to-cover ratio is presently 2.9 days.

Evaxion Biotech A/S Trading Down 27.2 %

Shares of EVAX stock opened at $4.37 on Wednesday. The company has a market capitalization of $5.11 million, a price-to-earnings ratio of -3.01 and a beta of -0.23. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. The firm has a 50-day moving average price of $5.25 and a 200 day moving average price of $11.01. Evaxion Biotech A/S has a twelve month low of $2.38 and a twelve month high of $36.90.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.40. The firm had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $0.19 million. Research analysts forecast that Evaxion Biotech A/S will post -0.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new position in Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. Institutional investors and hedge funds own 11.04% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.